Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:CVAC 10 August 2025 - 16 August 2025

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······

Stock Market Today

  • Freeport McMoRan (FCX) Undervalued Despite Recent Price Drop, Analysis Shows
    March 21, 2026, 12:53 PM EDT. Freeport-McMoRan's share price dropped 7.6% last week and 16.7% in the past month, trading at $52.09, yet remains up 31.2% over the past year. The company shows a strong long-term return of 69.3% over five years. A Discounted Cash Flow (DCF) model estimates its intrinsic value at $84.26 per share, suggesting the stock is undervalued by 38.2%. Despite a high price-to-earnings (P/E) ratio of 34.1x compared to industry averages, the DCF implies potential upside. Investors are weighing recent commodity market dynamics and metals sector shifts, making FCX a key focus for valuation analysis.
Go toTop